The MarketWatch News Department was not involved in the creation of this content. -- Topline data expected by year end -- Head-to-head studies of AL001 versus a marketed lithium carbonate product will ...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...
A wearable sensor could vastly improve treatment and drug safety for millions of patients who take lithium for bipolar disorder. Lithium is a highly effective treatment for bipolar disorder, but the ...
Compared with lithium, valproate, olanzapine, quetiapine, and risperidone generally exhibited a lower likelihood of thyroid dysfunction. HealthDay News — Lithium is associated with an increased risk ...
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure ...
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback